Citigroup Maintains Sell on Sarepta Therapeutics, Raises Price Target to $13

Benzinga Newsdesk www.benzinga.com Positive 81.4%

Neg 0% Neu 0% Pos 81.4%

Citigroup analyst Yigal Nochomovitz maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Sell and raises the price target from $9 to $13.